Hims & Hers Health, Inc. $HIMS Shares Bought by Renaissance Group LLC

Renaissance Group LLC grew its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 99.0% in the second quarter, HoldingsChannel reports. The fund owned 176,384 shares of the company’s stock after acquiring an additional 87,755 shares during the quarter. Renaissance Group LLC’s holdings in Hims & Hers Health were worth $8,793,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of HIMS. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at about $29,000. Bessemer Group Inc. lifted its position in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares in the last quarter. Spire Wealth Management acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $42,000. Webster Bank N. A. increased its holdings in Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after acquiring an additional 630 shares in the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the first quarter worth $30,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HIMS. Bank of America raised their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday. KeyCorp started coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $45.27.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Michael Chi sold 13,749 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $694,324.50. Following the sale, the insider owned 297,139 shares of the company’s stock, valued at approximately $15,005,519.50. The trade was a 4.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total value of $6,852,231.96. Following the completion of the transaction, the chief executive officer owned 160,425 shares in the company, valued at $8,579,529. This represents a 44.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 584,209 shares of company stock worth $31,837,916 in the last ninety days. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $36.36 on Wednesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The stock’s fifty day moving average is $50.12 and its two-hundred day moving average is $51.42. The firm has a market capitalization of $8.28 billion, a P/E ratio of 67.33, a price-to-earnings-growth ratio of 7.08 and a beta of 2.20. Hims & Hers Health, Inc. has a fifty-two week low of $20.02 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter in the prior year, the firm earned $0.32 EPS. The firm’s revenue was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has approved a stock buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to repurchase up to 3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.